Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Neuro-Oncology
Published in: Journal of Neuro-Oncology 3/2017

01-02-2017 | Laboratory Investigation

Correlation of higher levels of soluble TNF-R1 with a shorter survival, independent of age, in recurrent glioblastoma

Authors: Manmeet S. Ahluwalia, Stephanie Bou-Anak, Monica E. Burgett, Nehaw Sarmey, Divya Khosla, Saurabh Dahiya, Robert J. Weil, Eunnyung Bae, Ping Huang, Mary McGraw, Lisa M. Grove, Mitchell A. Olman, Richard A. Prayson, John H. Suh, G. Yancey Gillespie, Jill Barnholtz-Sloan, Amy S. Nowacki, Gene H. Barnett, Candece L. Gladson

Published in: Journal of Neuro-Oncology | Issue 3/2017

Login to get access

Abstract

The circulating levels of soluble tumor necrosis factor receptor-1 (sTNF-R1) and sTNF-R2 are altered in numerous diseases, including several types of cancer. Correlations with the risk of progression in some cancers, as well as systemic manifestations of the disease and therapeutic side-effects, have been described. However, there is very little information on the levels of these soluble receptors in glioblastoma (GBM). Here, we report on an exploratory retrospective study of the levels of sTNF-Rs in the vascular circulation of patients with GBM. Banked samples were obtained from 112 GBM patients (66 untreated, newly-diagnosed patients and 46 with recurrent disease) from two institutions. The levels of sTNF-R1 in the plasma were significantly lower in patients with newly-diagnosed or recurrent GBM than apparently healthy individuals and correlated with the intensity of expression of TNF-R1 on the tumor-associated endothelial cells (ECs) in the corresponding biopsies. Elevated levels of sTNF-R1 in patients with recurrent, but not newly-diagnosed GBM, were significantly associated with a shorter survival, independent of age (p = 0.02) or steroid medication. In contrast, the levels of circulating sTNF-R2 were significantly higher in recurrent GBM than healthy individuals and there was no significant correlation with expression of TNF-R2 on the tumor-associated ECs or survival time. The results indicate that larger, prospective studies are warranted to determine the predictive value of the levels of sTNF-R1 in patients with recurrent GBM and the factors that regulate the levels of sTNF-Rs in the circulation in GBM patients.
Appendix
Available only for authorised users
Literature
1.
Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, Russell WE, Castner BJ, Johnson RS, Fitzner JN, Boyce RW, Nelson N et al (1998) An essential role for ectodomain shedding in mammalian development. Science 282:1281–1284CrossRefPubMed
2.
Ferrucci L, Corsi A, Lauretani F, Bandinelli S, Bartali B, Taub DD, et al (2005) The origins of age-related proinflammatory state. Blood 105:2294–2299CrossRefPubMed
3.
Adamska A, Nikolajuk A, Karczewska-Kupczewska M, Kowalska I, Otziomek E, Gorska M, Straczkowski M (2012) Relationships between serum adiponectin and soluble TNFα receptors and glucose and lipid oxidation in lean and obese subjects. Acta Diabetol 49:17–24CrossRefPubMed
4.
5.
Aggarwal BB, Gupta SC, Kim JH (2012) Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 119:651–665CrossRefPubMedPubMedCentral
6.
Brenner D, Blaser H, Mak TW (2015) Regulation of tumor necrosis factor signaling: live or let die. Nat Rev Immunol 15:362–374CrossRefPubMed
7.
Carrlsson AC, Nordquist L, Larsson TE, Carrero J-J, Larsson A, Lind L, Arnlov J (2015) Soluble tumor necrosis factor receptor 1 is associated with glomerular filtration rate progression and incidence of chronic kidney disease in two community-based cohorts of elderly individuals. Cardiorenal Med 5:278–288.CrossRef
8.
Sharma S, Purohit S, Sharma A, Hopkins D, Steed L, Bode B, Anderson SW, Caldwell R, She J-X (2015) Elevated serum levels of soluble TNF receptors and adhesion molecules are associated with diabetic retinopathy in patients with type-1 diabetes. Mediators Inflamm. doi:10.​1155/​2015/​279393.PubMedPubMedCentral
9.
Kaminska J, Nowacki MP, Kowalska M, Rysinska A, Chwalinski M, Fuksiewicz M, Michalski W, Chechlinska M (2005) Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor type I–an independent prognostic factor. Tumour Biol 26:186–194CrossRefPubMed
10.
Kotowicz B, Kaminska J, Fuksiewicz M, Kowalska M, Jonska-Gmyrek J, Gawrychowski K, Sobotkowski J, Skrzypczak M, Starzewski J, Bidzinski M (2010) Clinical significance of serum CA-125 and soluble tumor necrosis factor receptor type I in cervical adenocarcinoma patients. Int J Gynecol Cancer 20:588–592CrossRefPubMed
11.
Burger RA, Darcy KM, DiSaia PJ, Monk BJ, Grosen EA, Gatanaga T, Granger GA, Wang J, Tian C, Hanjani P, Cohn DE (2004) Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy: a gynecologic oncology group study. Cancer 101:106–115CrossRefPubMed
12.
Kaminska J, Kowalska M, Kotowicz B, Fuksiewicz M, Glogowski M, Wojcik E, Chechlinska M, Steffen J (2006) Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF—an independent prognostic factor. Oncology 70:115–125CrossRefPubMed
13.
Dossus L, Becker S, Rinaldi S, Lukanova A, Tjonneland A, Olsen A, Overvad K, Chabbert-Buffet N, Boutron-Ruault M-C, Clavel-Chapelon F, Teucher B, Chang-Claude J, Pischon T et al (2011) Tumor necrosis factor (TNF)-α, soluble TNF receptors and endometrial cancer risk: the EPIC study. Int J Cancer 129:2032–2037CrossRefPubMed
14.
Chan AT, Ogino S, Giovannucci EL, Fuchs, CS (2011) Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. Gastroenterology 140:799–808CrossRefPubMed
15.
Heemann C, Kreuz M, Stoller I, Schoof N, von Bonin F, Ziepert M, Loffler M, Jung W, Pfreundschuh M, Trumper L, Kube D (2012) Circulating levels of TNF receptor II are prognostic for patients with peripheral T-cell non-Hodgkin lymphoma. Clin Cancer Res 18:3637–3647CrossRefPubMed
16.
Seruga B, Zhang H, Bernstein LJ, Tannock IF (2008) Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 8:887–899CrossRefPubMed
17.
Ammirati M, Rao S, Granger G (2001) Detection of TNF inhibitors (soluble receptors) in the sera and tumor cyst fluid of patients with malignant astrocytoma of the brain. Front Biosci 6:b17–24PubMed
18.
19.
Ganz PA, Bower JE, Kwan L, Castellon SA, Silverman DHS, Geist C, Breen EC, Irwin MR, Cole SW (2013) Does tumor necrosis factor-alpha (TNF-α) play a role in post-chemotherapy cerebral dysfunction? Brain Behav Immun 30:S99–S108CrossRefPubMed
20.
Patel SK, Wong AL, Wong FL, Breen EC, Hurria A, Smith M, Kinjo C, Paz IB, Kruper L, Somlo G, Mortimer JE, Palomares MR, Irwin MR, Bhatia S (2015) Inflammatory biomarkers, comorbidity, and neurocognition in women with newly diagnosed breast cancer. J Natl Cancer Inst. doi:10.​1093/​jnci/​djv131
21.
Misri S, Papagiannakopoulos T, Kinouchi K, Liu Y, Cervantes M, Baldi P, Jacks T, Sassone-Corsi P (2016) Lung adenocarcinoma distally rewires hepatic circadian homeostasis. Cell 165:896–909CrossRef
22.
Huang P, Rani MR, Ahluwalia MS, Bae E, Prayson RA, Weil RJ, Nowacki AS, Hedayat H, Sloan AE, Lathia JD, Rich JN, Tipps R, Gladson CL (2012) Endothelial expression of TNF receptor-1 generates a proapoptotic signal inhibited by integrin α6β1 in glioblastoma. Cancer Res 72:1428–1437CrossRefPubMedPubMedCentral
23.
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. doi:10.​1007/​s00401-016-1545-1
24.
Hardikar S, Song X, Kratz M, Anderson GL, Blount PL, Reid BJ, Vaughan TL, White E (2014) Intraindividual variability over time in plasma biomarkers of inflammation and effects of long-term storage. Cancer Causes Control 25:969–976CrossRefPubMedPubMedCentral
25.
Pai JK, Curhan GC, Cannuscio CC, Rifai N, Ridker PM, Rimm EB (2002) Stability of novel plasma markers associated with cardiovascular disease: processing within 36 h of specimen collection. Clin Chem 48(10):1781–1784PubMed
26.
Aziz N, Nishanian P, Mitsuyasu R, Detels R, Fahey JL (1999) Variables that affect assays for plasma cytokines and soluble activation markers. Clin Diagn Lab Immunol 6(1):89–95PubMedPubMedCentral
27.
Kumar R, Kamdar D, Madden L, Hills C, Crooks D, O’Brien D, Greenman J (2006) Th1/Th2 cytokine imbalance in meningioma, anaplastic astrocytoma and glioblastoma multiforme patients. Oncol Rep 15:1513–1516PubMed
28.
29.
Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110CrossRefPubMedPubMedCentral
30.
31.
Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, Cohen-Jonathan-Moyal E, Frappaz D, Henriksson R, Balana C, Chinot O, Ram Z, Reifenberger G, Soffietti R, Wick W (2014) EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 15:e395–e403CrossRefPubMed
32.
Wu B, Sha L, Wang Y, Xu W, Yu Y, Feng F, Sun C, Xia L (2014) Diagnostic and prognostic value of a disintegrin and metalloproteinase-17 in patients with gliomas. Oncol Lett 8:2616–2620PubMedPubMedCentral
33.
Lin J, Lemke C, Redies C, Yan X, Mix E, Rolfs A, Luo J (2011) ADAM17 overexpression promotes angiogenesis by increasing blood vessel sprouting and pericyte number during brain microvessel development. Int J Dev Biol 55:961–968CrossRefPubMed
34.
Zheng X, Jiang F, Katakowski M, Lu Y, Chopp M (2012) ADAM17 promotes glioma cell malignant phenotype. Mol Carcinog 51:150–164CrossRefPubMed
35.
Chen X, Chen L, Chen J, Hu W, Gao H, Xie B, Wang X, Yin Z, Li S (2013) ADAM17 promotes U87 glioblastoma stem cell migration and invasion. Brain Res 1538:151–158CrossRefPubMed
36.
Rose-Johns S (2013) ADAM17, shedding, TACE as therapeutic targets. Pharmacol Res 17:19–22CrossRef
37.
See AP, Parker JJ, Waziri A (2015) The role of regulatory T cells and microglia in glioblastoma-associated immunosuppression. J Neurooncol 123:405–412CrossRefPubMed
38.
Gousias K, Markou M, Arzoglou V, Voulgaris S, Vartholomatos G, Kostoula A, Voulgari P, Polyzoidis K, Kyritsis AP (2010) Frequent abnormalities of the immune system in gliomas and correlation with the WHO grading system of malignancy. J Neuroimmunol 226:136–142CrossRefPubMed
39.
40.
Silver DJ, Sinyuk M, Vogelbaum MA, Ahluwalia MS, Lathia JD (2016) The intersection of cancer, cancer stem cells, and the immune system: therapeutic opportunities. Neuro Oncol 18:153–159.CrossRefPubMed
41.
Zisakis A, Piperi C, Themistocleous MS, Korkolopoulou P, Boviatsis EI, Sakas DE, Patsouris E, Lea RW, Kalofoutis A (2007) Comparative analysis of peripheral and localised cytokine secretion in glioblastoma patients. Cytokine 39:99–105CrossRefPubMed
42.
Reynes G, Vila V, Martin M, Parada A, Fleitas T, Reganon E, Martinez-Sales V (2011) Circulating markers of angiogenesis, inflammation and coagulation in patients with glioblastoma. J Neurooncol 102:35–41CrossRefPubMed
43.
Kato T, Sawamura Y, Tada M, Sakuma S, Sudo M, Abe H (1995) p55 and p75 tumor necrosis factor receptor expression on human glioblastoma cells. Neurol Med Chir (Tokyo) 35:567–574CrossRef
44.
Haghikia A, Ladage K, Lafenetre P, Hinkerohe D, Smikalla D, Haase CG, Dermietzel R, Faustmann PM (2008) Intracellular application of TNF-alpha impairs cell to cell communication via gap junctions in glioma cells. J Neurooncol 86:143–152CrossRefPubMed
45.
Chen TC, Hinton DR, Sippy BD, Hofman FM (1997) Soluble TNF-alpha receptors are constitutively shed and downregulate adhesion molecule expression in malignant gliomas. J Neuropathol Exp Neurol 56:541–550CrossRefPubMed
46.
Jain R, Poisson L, Narang J, Scarpace L, Rosenblum ML, Rempel S, Mikkelsen T (2012) Correlation of perfusion parameters with genes related to angiogenesis regulation in glioblastoma: a feasibility study. AJNR Am J Neuroradiol 33:1343–1348CrossRefPubMed
47.
Rego SL, Swamydas M, Kidiyoor A, Helms R, De Piante A, Lance AL, Mukherjee P, Dreau D (2013) Soluble tumor necrosis factor receptors shed by breast tumor cells inhibit macrophage chemotaxis. J Interferon Cytokine Res 33:672–681CrossRefPubMed
48.
Bai Y-M, Su T-P, Li CT, Tsai SJ, Chen M-H, Tu P-C, Chiou W-F (2015) Comparison of pro-inflammatory cytokines among patients with bipolar disorder and unipolar depression and normal controls. Bipolar Disord 17:269–277CrossRefPubMed
49.
Yamamori H, Ishima T, Yasuda Y, Fujimoto M, Kudo N, Ohi K, Hashimoto K, Takeda M, Hashimoto R (2016) Assessment of a multi-assay biological diagnostic test for mood disorders in a Japanese population. Neurosci Lett 612:167–171CrossRefPubMed
Metadata
Title
Correlation of higher levels of soluble TNF-R1 with a shorter survival, independent of age, in recurrent glioblastoma
Authors
Manmeet S. Ahluwalia
Stephanie Bou-Anak
Monica E. Burgett
Nehaw Sarmey
Divya Khosla
Saurabh Dahiya
Robert J. Weil
Eunnyung Bae
Ping Huang
Mary McGraw
Lisa M. Grove
Mitchell A. Olman
Richard A. Prayson
John H. Suh
G. Yancey Gillespie
Jill Barnholtz-Sloan
Amy S. Nowacki
Gene H. Barnett
Candece L. Gladson
Publication date
01-02-2017
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 3/2017
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-016-2319-2

Other articles of this Issue 3/2017

Journal of Neuro-Oncology 3/2017 Go to the issue

Clinical Study

Longitudinal experience with WHO Grade III (anaplastic) meningiomas at a single institution

Clinical Study

Incidence of seizure in adult patients with intracranial metastatic disease

Clinical Study

The effect of IDH1 mutation on the structural connectome in malignant astrocytoma

Clinical Study

Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial

Clinical Study

Multisession gamma knife surgery for large brain metastases

Laboratory Investigation

The inhibiting activity of meadowsweet extract on neurocarcinogenesis induced transplacentally in rats by ethylnitrosourea